[Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial].
AIM of this study was the assessment of the radiation exposure from preparation and application of (90)Y-Zevalin, the measurement of the dose rate at the patient, the exposure of family members as well as the determination of the activity concentration in urine of patients.


METHODS
Overall data from 31 therapeutic administrations carried out in four institutions were evaluated. During preparation and application of (90)Y-Zevalin the finger exposures of radiochemists, technicians, and physicians were measured. The dose rate of the patient was measured immediately after radioimmunotherapy. In patients treated in a nuclear medicine therapy unit, urine was collected over a two day period and the corresponding activity was determined. Family members of outpatients were asked to wear a dosimeter over a seven day period.


RESULTS
During the preparation we found a maximum skin dose of 6 mSv at the average, and during application of 3 mSv, respectively. After administration of (90)Y the dose rate was 0.4 +/- 0.1 microSv/h at 2 m distance. Urine measurements yielded a cumulated 24 h excretion of 3.9 +/- 1.4% and 4.4 +/- 1.4% within 48 h, respectively, that is equivalent to 43 +/- 18 and 50 +/- 20 MBq of (90)Y, respectively. Family members received a radiation exposure of 40 +/- 14 microSv over seven days.


CONCLUSIONS
During preparation and application of (90)Y-Zevalin appropriate radiation shielding is necessary. For family members as well as nursing staff no additional special radiation protection measures beyond those being common for other nuclear medicine procedures are necessary.
Geworski
L
L
Klinik für Nuklearmedizin, Charité, Universitätsmedizin Berlin, Schumannstr. 20/21, 10098 Berlin. lilli.geworski@charite.de
Zöphel
K
K
Rimpler
A
A
Barth
I
I
Lassmann
M
M
Sandrock
D
D
Zander
A
A
Halm
T
T
Hänscheid
H
H
Hofmann
M
M
Reiners
Chr
C
Munz
D L
DL
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine; D005385:Fingers; D006801:Humans; D008657:Metabolic Clearance Rate; D011446:Prospective Studies; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D012867:Skin / Q000528:radiation effects*; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000652:urine
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan